New drug AU409 enters first human trial for tough liver cancers
NCT ID NCT05791448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumors. The study is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AU409
- What this could lead to
- If successful, this could point toward a new treatment option for advanced liver cancers and tumors that have spread to the liver.
- What could go wrong
- This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. The drug may not prove effective, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles County-USC Medical Center
RECRUITINGLos Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b